Molecular probes targeting HER2 PET/CT and their application in advanced breast cancer

J Cancer Res Clin Oncol. 2024 Mar 11;150(3):118. doi: 10.1007/s00432-023-05519-y.

Abstract

Purpose: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer cases are among the most aggressive breast tumor subtypes. Accurately assessing HER2 expression status is vital to determining whether patients will benefit from targeted anti-HER2 treatment. HER2-targeted positron emission tomography (PET/CT) is noninvasive, enabling the real-time evaluation of breast cancer patient HER2 status with accuracy.

Methods: We summarize the research progress of PET/CT targeting HER2 in breast cancer, focusing on PET/CT molecular probes targeting HER2 and their clinical application in the management of advanced breast cancer.

Results: At present, a variety of different HER2 targeted molecular probes for PET/CT imaging have been developed, including nucleolin-labeled antibodies, antibody fragments, nanobodies, and peptides of various affinities, among others. HER2-targeted PET/CT can relatively accurately evaluate HER2 expression status in advanced breast cancer patients. It has good performance in the early detection of small HER2-positive lesions, evaluation of HER2 status in lesions that cannot be readily biopsied, evaluation of the heterogeneity of multiple metastases, identification of lesions with altered HER2 status, and evaluation of the efficacy of anti-HER2 drugs.

Conclusion: HER2-targeted PET/CT offers a promising noninvasive approach for real-time assessment of HER2 status,which can be guide targeted treatment for HER2-positive breast cancer patients. Future prospective clinical studies will be invaluable for fully evaluating the importance of HER2-targeted molecular imaging in the management of breast cancer.

Keywords: Advanced breast cancer; Clinical applications; HER2; Molecular probes; PET/CT.

Publication types

  • Review

MeSH terms

  • Breast Neoplasms* / metabolism
  • Female
  • Humans
  • Positron Emission Tomography Computed Tomography* / methods
  • Positron-Emission Tomography
  • Prospective Studies
  • Receptor, ErbB-2 / metabolism

Substances

  • Receptor, ErbB-2